Acura Pharmaceuticals (ACUR) 0.85 $ACUR FDA acc
Post# of 64074
Posted On: 02/28/2015 7:25:20 PM
Acura Pharmaceuticals (ACUR) 0.85 $ACUR
FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST
MNK: 116.72 (-2.89), LCI: 62.40 (-2.77), ACT: 291.36 (+1.58), EGLT: 15.01 (+0.03), ZGNX: 1.68 (+0.03), PFE: 34.32 (-0.27), ABBV: 60.50 (-0.02), TEVA: 57.02 (+0.53), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
Elite Pharma set to begin abuse-deterrent opioid Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 9:06PM CST
MNK: 116.72 (-2.89), LCI: 62.40 (-2.77), EGLT: 15.01 (+0.03), ACT: 291.36 (+1.58), ZGNX: 1.68 (+0.03), PFE: 34.32 (-0.27), ABBV: 60.50 (-0.02), TEVA: 57.02 (+0.53), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
FDA accepts Collegium's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 7:40AM CST
MNK: 116.72 (-2.89), LCI: 62.40 (-2.77), EGLT: 15.01 (+0.03), ACT: 291.36 (+1.58), ZGNX: 1.68 (+0.03), PFE: 34.32 (-0.27), ABBV: 60.50 (-0.02), TEVA: 57.02 (+0.53), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
Acura Pharmaceuticals begins clinical study of experimental meth-resistant Nexafed extended-release formulations with improved Impede 2.0 Technology
M2 - Tue Feb 17, 3:11AM CST
Pharmaceutical company Acura Pharmaceuticals (NasdaqCM:ACUR) disclosed on Monday that it has launched a pilot clinical study of NEXAFED (pseudoephedrine HCl) extended-release tablets utilising its second generation methamphetamine resistant technology, IMPEDE 2.0.
ACUR: 0.85 (+0.09)
Acura Pharmaceuticals Initiates Clinical Study of Meth-Resistant Nexafed(R) Extended-Release Formulations
Marketwired - Mon Feb 16, 5:30AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today announced the initiation of treatment in a pilot clinical study of two experimental formulations of NEXAFED (pseudoephedrine HCl) extended-release tablets employing Acura's 2nd generation methamphetamine resistant technology, IMPEDE 2.0. The study in fasted, healthy subjects will measure the systemic absorption of the active ingredient, pseudoephedrine, from two experimental NEXAFED extended-release formulations compared to an FDA-approved 12-hour extended-release reference product. The objective of the study is to characterize the bioavailability profile of the NEXAFED formulations for possible adjustment before pivotal human pharmacokinetic testing is undertaken.
ACUR: 0.85 (+0.09)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 3.02 (+0.04), INSM: 18.54 (+0.38), RNN: 0.80 (unch), ZSPH: 49.47 (-0.50), RDHL: 14.17 (+0.12), ASPX: 67.24 (-3.07), ACUR: 0.85 (+0.09), XNPT: 6.85 (unch), SPNC: 33.81 (+0.37), CORI: 6.92 (+0.02), SAGE: 43.45 (+0.46), EBIO: 10.57 (+0.17), HAE: 44.46 (-0.79), JAZZ: 170.09 (-5.10), ICPT: 221.37 (+2.30), NVDQ: 16.55 (-0.10)
Acura Pharmaceuticals Expands Meth-Resistant Decongestant Line With NEXAFED(R) Sinus Pressure + Pain
Marketwired - Thu Feb 05, 5:15AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced the launch of their second pseudoephedrine (PSE) product, NEXAFED® Sinus Pressure + Pain. NEXAFED Sinus Pressure + Pain [pseudoephedrine HCI 30mg + acetaminophen 325mg] is a meth-resistant immediate-release tablet that effectively relieves congestion due to colds and allergies, as well as pain and/or fever associated with colds and sinus headaches. NEXAFED Sinus Pressure + Pain will continue to utilize NEXAFED's unique, patented IMPEDE® technology that disrupts the conversion of PSE into the dangerous drug methamphetamine (meth), and will be the first meth-resistant PSE combination sinus medicine available.
ACUR: 0.85 (+0.09)
Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market
Matt's Stocks - Seeking Alpha - Thu Jan 29, 7:06AM CST
The past year for Elite Pharmaceuticals ( OTCQB:ELTP ) has been quite remarkable. While the stock price has taken investors on a bit of a roller coaster ride, the company's business trajectory has been exceptional. In the past year, we have seen...
EGLT: 15.01 (+0.03), ACT: 291.36 (+1.58), PFE: 34.32 (-0.27), ACUR: 0.85 (+0.09)
Egalet up on HAL study
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 10:38AM CST
EGLT: 15.01 (+0.03), ZGNX: 1.68 (+0.03), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
Direction of Market Influences: New Coverage of Acorda, Acura Pharmaceuticals, Adamas, Adamis and Addus HomeCare
PR Newswire - Wed Jan 14, 6:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Acorda (NASDAQ: ACOR), Acura Pharmaceuticals (NASDAQ: ACUR), Adamas (NASDAQ: ADMS), Adamis (NASDAQ: ADMP), and Addus HomeCare (NASDAQ: ADUS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADMS: 17.28 (+0.08), ADUS: 21.90 (+0.32), ADMP: 6.42 (-0.02), ACOR: 33.84 (-1.72), ACUR: 0.85 (+0.09)
Acura inks deal with Egalet to commercialize oxycodone product
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:17AM CST
EGLT: 15.01 (+0.03), ACUR: 0.85 (+0.09)
Acura Pharmaceuticals Partners With Egalet Corporation to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
Marketwired - Thu Jan 08, 5:00AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that the Company has entered into a Collaboration and License Agreement (the "Agreement"
with Egalet US, Inc. and Egalet Ltd. (together "Egalet", subsidiaries of Egalet Corporation (NASDAQ: EGLT), which is also a party to the Agreement with obligations thereunder) granting Egalet exclusive worldwide rights to commercialize Acura's immediate release oxycodone hydrochloride tablets product which incorporates Acura's patented Aversion® (abuse-deterrent) Technology platform. The licensed product, formerly known as Oxecta, will be marketed by Egalet under the name OXAYDO(TM). OXAYDO is FDA approved in 5mg and 7.5mg strengths for the treatment of acute and chronic moderate to severe pain.
EGLT: 15.01 (+0.03), ACUR: 0.85 (+0.09)
Endo and BioDelivery Sciences submit NDA for transmucosal pain med
Seeking Alpha - at Seeking Alpha - Thu Dec 25, 11:41AM CST
MNK: 116.72 (-2.89), BDSI: 14.99 (+0.28), ENDP: 85.60 (+0.36), EGLT: 15.01 (+0.03), ZGNX: 1.68 (+0.03), PFE: 34.32 (-0.27), TEVA: 57.02 (+0.53), ABBV: 60.50 (-0.02), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
Acura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy
Marketwired - Tue Dec 23, 5:00AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today acknowledged the announcement by Kmart Pharmacy that Kmart is stocking NEXAFED [pseudoephedrine hydrochloride (HCl)], Acura's next generation pseudoephedrine with methamphetamine-resistant IMPEDE technology, in all Kmart in-store pharmacies nationwide (http://www.pharmacytimes.co m/sap-news/Kmart-Pharmacy-Takes-Step-to-Battle-Methamphetamine).
ACUR: 0.85 (+0.09)
Acura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations
Marketwired - Mon Dec 08, 5:30AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company has been issued U.S. Patent No. 8,901,113 by the United States Patent and Trademark Office.
ACUR: 0.85 (+0.09)
FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 12:36PM CST
MNK: 116.72 (-2.89), EGLT: 15.01 (+0.03), ZGNX: 1.68 (+0.03), PFE: 34.32 (-0.27), TEVA: 57.02 (+0.53), ABBV: 60.50 (-0.02), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST
MNK: 116.72 (-2.89), LCI: 62.40 (-2.77), ACT: 291.36 (+1.58), EGLT: 15.01 (+0.03), ZGNX: 1.68 (+0.03), PFE: 34.32 (-0.27), ABBV: 60.50 (-0.02), TEVA: 57.02 (+0.53), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
Elite Pharma set to begin abuse-deterrent opioid Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 9:06PM CST
MNK: 116.72 (-2.89), LCI: 62.40 (-2.77), EGLT: 15.01 (+0.03), ACT: 291.36 (+1.58), ZGNX: 1.68 (+0.03), PFE: 34.32 (-0.27), ABBV: 60.50 (-0.02), TEVA: 57.02 (+0.53), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
FDA accepts Collegium's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 7:40AM CST
MNK: 116.72 (-2.89), LCI: 62.40 (-2.77), EGLT: 15.01 (+0.03), ACT: 291.36 (+1.58), ZGNX: 1.68 (+0.03), PFE: 34.32 (-0.27), ABBV: 60.50 (-0.02), TEVA: 57.02 (+0.53), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
Acura Pharmaceuticals begins clinical study of experimental meth-resistant Nexafed extended-release formulations with improved Impede 2.0 Technology
M2 - Tue Feb 17, 3:11AM CST
Pharmaceutical company Acura Pharmaceuticals (NasdaqCM:ACUR) disclosed on Monday that it has launched a pilot clinical study of NEXAFED (pseudoephedrine HCl) extended-release tablets utilising its second generation methamphetamine resistant technology, IMPEDE 2.0.
ACUR: 0.85 (+0.09)
Acura Pharmaceuticals Initiates Clinical Study of Meth-Resistant Nexafed(R) Extended-Release Formulations
Marketwired - Mon Feb 16, 5:30AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today announced the initiation of treatment in a pilot clinical study of two experimental formulations of NEXAFED (pseudoephedrine HCl) extended-release tablets employing Acura's 2nd generation methamphetamine resistant technology, IMPEDE 2.0. The study in fasted, healthy subjects will measure the systemic absorption of the active ingredient, pseudoephedrine, from two experimental NEXAFED extended-release formulations compared to an FDA-approved 12-hour extended-release reference product. The objective of the study is to characterize the bioavailability profile of the NEXAFED formulations for possible adjustment before pivotal human pharmacokinetic testing is undertaken.
ACUR: 0.85 (+0.09)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 3.02 (+0.04), INSM: 18.54 (+0.38), RNN: 0.80 (unch), ZSPH: 49.47 (-0.50), RDHL: 14.17 (+0.12), ASPX: 67.24 (-3.07), ACUR: 0.85 (+0.09), XNPT: 6.85 (unch), SPNC: 33.81 (+0.37), CORI: 6.92 (+0.02), SAGE: 43.45 (+0.46), EBIO: 10.57 (+0.17), HAE: 44.46 (-0.79), JAZZ: 170.09 (-5.10), ICPT: 221.37 (+2.30), NVDQ: 16.55 (-0.10)
Acura Pharmaceuticals Expands Meth-Resistant Decongestant Line With NEXAFED(R) Sinus Pressure + Pain
Marketwired - Thu Feb 05, 5:15AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced the launch of their second pseudoephedrine (PSE) product, NEXAFED® Sinus Pressure + Pain. NEXAFED Sinus Pressure + Pain [pseudoephedrine HCI 30mg + acetaminophen 325mg] is a meth-resistant immediate-release tablet that effectively relieves congestion due to colds and allergies, as well as pain and/or fever associated with colds and sinus headaches. NEXAFED Sinus Pressure + Pain will continue to utilize NEXAFED's unique, patented IMPEDE® technology that disrupts the conversion of PSE into the dangerous drug methamphetamine (meth), and will be the first meth-resistant PSE combination sinus medicine available.
ACUR: 0.85 (+0.09)
Elite Pharmaceuticals Is Well Positioned To Address $7B Abuse Deterrent Opioid Market
Matt's Stocks - Seeking Alpha - Thu Jan 29, 7:06AM CST
The past year for Elite Pharmaceuticals ( OTCQB:ELTP ) has been quite remarkable. While the stock price has taken investors on a bit of a roller coaster ride, the company's business trajectory has been exceptional. In the past year, we have seen...
EGLT: 15.01 (+0.03), ACT: 291.36 (+1.58), PFE: 34.32 (-0.27), ACUR: 0.85 (+0.09)
Egalet up on HAL study
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 10:38AM CST
EGLT: 15.01 (+0.03), ZGNX: 1.68 (+0.03), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
Direction of Market Influences: New Coverage of Acorda, Acura Pharmaceuticals, Adamas, Adamis and Addus HomeCare
PR Newswire - Wed Jan 14, 6:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Acorda (NASDAQ: ACOR), Acura Pharmaceuticals (NASDAQ: ACUR), Adamas (NASDAQ: ADMS), Adamis (NASDAQ: ADMP), and Addus HomeCare (NASDAQ: ADUS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADMS: 17.28 (+0.08), ADUS: 21.90 (+0.32), ADMP: 6.42 (-0.02), ACOR: 33.84 (-1.72), ACUR: 0.85 (+0.09)
Acura inks deal with Egalet to commercialize oxycodone product
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:17AM CST
EGLT: 15.01 (+0.03), ACUR: 0.85 (+0.09)
Acura Pharmaceuticals Partners With Egalet Corporation to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology
Marketwired - Thu Jan 08, 5:00AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that the Company has entered into a Collaboration and License Agreement (the "Agreement"
with Egalet US, Inc. and Egalet Ltd. (together "Egalet", subsidiaries of Egalet Corporation (NASDAQ: EGLT), which is also a party to the Agreement with obligations thereunder) granting Egalet exclusive worldwide rights to commercialize Acura's immediate release oxycodone hydrochloride tablets product which incorporates Acura's patented Aversion® (abuse-deterrent) Technology platform. The licensed product, formerly known as Oxecta, will be marketed by Egalet under the name OXAYDO(TM). OXAYDO is FDA approved in 5mg and 7.5mg strengths for the treatment of acute and chronic moderate to severe pain. EGLT: 15.01 (+0.03), ACUR: 0.85 (+0.09)
Endo and BioDelivery Sciences submit NDA for transmucosal pain med
Seeking Alpha - at Seeking Alpha - Thu Dec 25, 11:41AM CST
MNK: 116.72 (-2.89), BDSI: 14.99 (+0.28), ENDP: 85.60 (+0.36), EGLT: 15.01 (+0.03), ZGNX: 1.68 (+0.03), PFE: 34.32 (-0.27), TEVA: 57.02 (+0.53), ABBV: 60.50 (-0.02), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
Acura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy
Marketwired - Tue Dec 23, 5:00AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today acknowledged the announcement by Kmart Pharmacy that Kmart is stocking NEXAFED [pseudoephedrine hydrochloride (HCl)], Acura's next generation pseudoephedrine with methamphetamine-resistant IMPEDE technology, in all Kmart in-store pharmacies nationwide (http://www.pharmacytimes.co m/sap-news/Kmart-Pharmacy-Takes-Step-to-Battle-Methamphetamine).
ACUR: 0.85 (+0.09)
Acura Pharmaceuticals Receives Additional U.S. Patent for Abuse Deterrent Drug Formulations
Marketwired - Mon Dec 08, 5:30AM CST
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company has been issued U.S. Patent No. 8,901,113 by the United States Patent and Trademark Office.
ACUR: 0.85 (+0.09)
FDA clears Purdue's abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 12:36PM CST
MNK: 116.72 (-2.89), EGLT: 15.01 (+0.03), ZGNX: 1.68 (+0.03), PFE: 34.32 (-0.27), TEVA: 57.02 (+0.53), ABBV: 60.50 (-0.02), ALKS: 70.25 (-0.98), ACUR: 0.85 (+0.09)
(0)
(0)Scroll down for more posts ▼